New Amsterdam Genomics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Founded in 2021 and headquartered in Cambridge, Massachusetts, New Amsterdam Genomics is a private, AI-driven health technology company positioned at the intersection of genomics, bioinformatics, and clinical care. Its core offering is a proprietary AI platform that analyzes a customer's full genome alongside continuous scientific literature to provide personalized risk assessments and health recommendations directly to consumers, healthcare providers, and enterprises. The company claims a significantly higher rate of 'life-changing' reports compared to competitors by examining all ~22,000 genes and dynamically updating its analyses with new research, targeting major areas like cancer, cardiac health, chronic diseases, and medication optimization.

OncologyCardiologyNeurologyMetabolic DiseasesAutoimmune DiseasesRare Diseases

Technology Platform

Proprietary AI platform integrating whole-genome sequencing data with lab values and continuous scientific literature ingestion via NLP to generate personalized health risk reports and actionable care recommendations.

Opportunities

The growing demand for proactive, personalized healthcare and the expansion of value-based care models create a large addressable market for N.A.G.'s AI-driven insights.

The company can leverage its comprehensive genomic data asset to forge lucrative partnerships with pharmaceutical companies for drug discovery and development, and with health systems for population health management.

Risk Factors

Key risks include the need for extensive clinical validation to support health outcome claims, potential regulatory scrutiny as the platform influences medical decisions, and intense competition from both DTC genetic testing firms and large technology companies entering the AI-health space.

Data privacy and security for highly sensitive genomic information is also a paramount concern.

Competitive Landscape

N.A.G. competes in a crowded field including DTC genetic test providers (e.g., 23andMe, AncestryHealth), clinical genetic testing labs (e.g., Invitae, Color Genomics), and emerging AI-health platforms from tech giants. Its primary differentiator is the claimed comprehensiveness of its whole-genome analysis coupled with a dynamic AI that updates with new research, aiming to provide deeper, more actionable insights than standard SNP-based reports.

More companies in AI / Machine Learning →More companies in United States →